Stay updated on Oncolytics Biotech Press Releases

Sign up to get notified when there's something new on the Oncolytics Biotech Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Oncolytics Biotech Press Releases page

  1. Check
    5 days ago
    Change Detected
    Summary
    Represents updated intraday stock data on the Investor Overview page, showing the current price of $0.89 and a daily decline of -$0.033 (-3.59%). This replaces the previous price of $0.90 and -$0.002 (-0.22%).
    Difference
    0.8%
    Check dated 2026-07-11T04:50:34.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The stock quote on the investor page now shows a current price of $0.90 with a daily change of -0.002 (-0.22%). The previous quote was $0.95 with -0.028 (-3.04%).
    Difference
    0.8%
    Check dated 2026-07-03T23:27:21.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Investor quote updated to $0.95 and 3.04%, replacing the previous $0.96 and 3.00%.
    Difference
    0.6%
    Check dated 2026-06-26T23:57:48.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    Stock data on the Investor Overview has been updated to include new price and percentage figures, replacing the previous values. A new press release about pelareorep manufacturing patent protection through 2044 has been added, and an older ASCO-related press release has been removed.
    Difference
    3%
    Check dated 2026-06-19T22:09:23.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Stock price changed from $0.83 (-$0.036, -4.15%) to $0.81 (-$0.012, -1.46%). This reflects updated pricing and daily performance data for the stock.
    Difference
    0.8%
    Check dated 2026-06-12T16:05:55.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    Stock information on the Investor Overview page was updated to reflect a current price of $0.87 with a change of -$0.013 and -1.48% on June 2, 2026. New items were added announcing Steve Glover's appointment to the Board and John McAdory's promotion to COO (June 1–2, 2026) and positive preclinical findings for pelareorep in combination with RAS-targeted approaches, while older items about durable responses in second-line RAS-Mutant MSS colorectal cancer and FDA alignment on a planned anal cancer study were removed.
    Difference
    3%
    Check dated 2026-06-05T11:45:52.000Z thumbnail image

Stay in the know with updates to Oncolytics Biotech Press Releases

Enter your email address, and we'll notify you when there's something new on the Oncolytics Biotech Press Releases page.